Loading...
XSHE
002603
Market cap4.30bUSD
Dec 05, Last price  
18.19CNY
1D
0.06%
1Q
10.98%
Jan 2017
47.77%
IPO
40.25%
Name

Shijiazhuang Yiling Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002603 chart
P/E
P/S
4.67
EPS
Div Yield, %
1.65%
Shrs. gr., 5y
Rev. gr., 5y
2.26%
Revenues
6.51b
-36.88%
938,555,9531,632,330,9861,649,320,0721,953,211,4301,648,676,3442,490,161,5332,921,157,2573,184,752,3683,820,158,7284,081,266,6544,814,557,8225,825,294,4988,782,479,67610,116,793,93712,532,841,02810,318,312,8516,512,734,471
Net income
-725m
L
122,117,123297,182,764315,559,119454,071,087185,806,390244,291,460354,495,205430,491,010542,023,195540,705,102599,221,880606,501,0701,218,737,6791,343,856,0072,362,756,4841,352,379,242-724,515,582
CFO
611m
+293.04%
210,177,689318,211,329299,717,830070,128,56955,322,427105,904,047131,877,728631,641,569114,652,88772,366,62968,925,4491,586,172,733528,693,7143,487,736,416155,457,433611,013,171
Dividend
Jul 19, 20240.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of medicine primarily in China. The company operates through Chemical and Biological Medicine, and Health Industry segments. It offers drugs for cardiac and premature ventricular beats, sinus bradycardia, chronic heart failure, integrated rhythm regulation, cold and respiratory, cardiovascular and cerebrovascular diseases, diabetes field, tumor medication, and others. The company sells its products through physical display and online. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
IPO date
Jul 28, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT